BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane

European Journal of Surgical Oncology

Volumn 42, Issue 7, 2016, Pages 999-1001

  Ishikawa, T ^a   Narui, K ^b   Tanabe, M ^b   Kida, K ^b   Oba, M S ^b   Yamada, A ^b   Ichikawa, Y ^c   Endo, I ^c  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Basal like; BRCAness; Breast cancer; Cancer stem cell; Triple negative

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; TAXANE DERIVATIVE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN, HUMAN; BRIDGED COMPOUND; TAXANE; TAXOID;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; BRCA1 FUNCTION DEFICIENT BREAST CANCER; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEEDLE BIOPSY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIPLE NEGATIVE BREAST CANCER; AGED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG RESISTANCE; METABOLISM; MULTIPLEX POLYMERASE CHAIN REACTION; PATHOLOGY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BRIDGED-RING COMPOUNDS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; TAXOIDS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84962069479     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2016.02.246     Document Type: Article

References (5)

1. 1 Lips, E.H., Laddach, N., Savola, S.P., et al. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res, 13(5), 2011 Oct 27, R107.
2. 2 Ginestier, C., Hur, M.H., Charafe-Jauffret, E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:5 (2007), 555–567.
3. 3 Ishikawa, T., Shimizu, D., Tanabe, M., et al. A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study. Presented in a General Poster Session at the 2013 ASCO Annual Meeting. J Clin Oncol, 31, 2013 (suppl; abstr 1047).
4. 4 James, C.R., Quinn, J.E., Mullan, P.B., Johnston, P.G., Harkin, D.P., BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 12:2 (2007), 142–150.
5. 5 Tutt, A., Ellis, P., Kilbum, L., et al. A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. San Antonio Breast Cancer Symposium. 2014 [Abstract]. Available at: http://www.careeducation.ca/news/2014/12/19/sabcs-2014-abstract-s3-01-breast-cancer-the-tnt-trial.